-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Intellectual Property
Biotech, Gates Foundation, and Global Health
Great interview by Gene Quinn with Erik Iverson, Associate General Counsel with the Bill & Melinda Gates Foundation. A summary article is on BIOtech Now and the full interview can be found on IPWatchdog.com. Highlights: Iverson told me in no uncertain terms, “[A] fundamental premise at the foundation is that we absolutely respect intellectual property rights. We recognize their importance and we certainly recognize the importance of companies and their involvement in developing products and having Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
BIO Hails Senate Passage of America Invents Act
BIO Hails Senate Passage of America Invents Act Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate: “BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5. We appreciate Read More >
BIO Comments to USTR on 2011 Special 301 Review
BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)
BIO’s Intellectual Property Counsels’ Committee Spring Conference and Meeting: Seattle
Over the past eight years, BIO’s semiannual IP Counsels Committee Conference has become a popular and growing event among our members’ IP and legal professionals. Our upcoming 2011 Spring IPCC Conference in Seattle, WA on April 13-15 will be an excellent opportunity for IP professionals to hear, listen, and learn about current and projected topics related to biotechnology IP. We invite you to join us in an informal, fun and informative setting to meet fellow in-house Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
Tags: BIO, biosimilars, biotechnology, Biotechnology Industry Organization, double patenting, emerging markets, Ethics for In-House IP Attorneys, Intellectual Property, Intellectual Property Counsels' Committee, IP Counsels' Committee, IPCC, Myriad, Seattle, Stanford v. Roche
PTO Director Kappos Remarks at Innovation Alliance Conference: IP leads to job growth
Thank you Roger [Martin], for that kind introduction. I would like to thank the Innovation Alliance for having me in today to speak with you about intellectual property’s vital role in today’s innovation economy. America stands at a critical juncture in our economic evolution, and intellectual property will play a key role in driving our economic growth and renewal. As technological advances bring great change to the speed and complexity of American innovation, strong intellectual Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Axletech International, backlog reduction, Bayh-Dole, Chairman Leahy, Court of Appeals for the Federal Circuit, David Kappos, Department of Commerce, Director Kappos, economic development, economic growth, Green Technology, Harvard Business Review, Innovation Alliance, Intellectual Property, International, IP policy, job growth, Obama Administration, patent, Patent Reform, patents, PTO, Track 1, United States Patent and Trademark Office, USPTO, Xencor
Tags: Axletech International, backlog reduction, Bayh-Dole, Chairman Leahy, Court of Appeals for the Federal Circuit, David Kappos, Department of Commerce, Director Kappos, economic development, economic growth, Green Technology, Harvard Business Review, Innovation Alliance, Intellectual Property, International, IP policy, job growth, Obama Administration, patent, Patent Reform, patents, PTO, Track 1, United States Patent and Trademark Office, USPTO, Xencor
